R. Nolan Townsend has served as Lexeo Therapeutics Chief Executive Officer and member of the Board of Directors since January 2020. Lexeo Therapeutics is a New York City-based, clinical stage biotechnology company that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic diseases.
Prior to Lexeo, Mr. Townsend held roles as President, Pfizer Rare Disease for the North America region and President, Pfizer Rare Disease for the International markets; overseeing overall strategy, the cross functional organization and operating budget in those regions. Mr. Townsend has over a decade of experience with Pfizer first joining the company in Corporate Finance and subsequently in roles of increasing responsibility across Corporate Finance, Corporate Strategy, Operations, Marketing, General Management and Commercial leadership in Pfizer’s New York headquarters, Asia, Africa/Middle East and Europe. Prior to Pfizer, Mr. Townsend worked in the healthcare investment banking group at Lehman Brothers, advising healthcare companies on strategic financing transactions and mergers and acquisitions.
Mr. Townsend currently serves on the Board of Directors of Arbor Biotechnologies, the Biotechnology Innovation Organization (BIO), and the Martha’s Vineyard Museum, in addition to an appointment to the New York City Economic Development Corporation’s Life Sciences Advisory Council. Mr. Townsend previously served as Chairman of the Board and is currently an Advisor to Life Science Cares New York.
Mr. Townsend received his Masters in Business Administration from the Harvard Business School and his Bachelor of Arts in Economics from the University of Pennsylvania.
What is Richard Nolan Townsend's net worth?
The estimated net worth of Richard Nolan Townsend is at least $2.18 million as of April 6th, 2026. Townsend owns 340,106 shares of Lexeo Therapeutics stock worth more than $2,183,481 as of April 21st. This net worth evaluation does not reflect any other investments that Townsend may own. Learn More about Richard Nolan Townsend's net worth.
How do I contact Richard Nolan Townsend?
Has Richard Nolan Townsend been buying or selling shares of Lexeo Therapeutics?
During the last ninety days, Richard Nolan Townsend has sold $312,950.00 of Lexeo Therapeutics stock. Most recently, Richard Nolan Townsend sold 55,000 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $5.69, for a transaction totalling $312,950.00. Following the completion of the sale, the chief executive officer now directly owns 340,106 shares of the company's stock, valued at $1,935,203.14. Learn More on Richard Nolan Townsend's trading history.
Are insiders buying or selling shares of Lexeo Therapeutics?
In the last twelve months, insiders at the sold shares 18 times. They sold a total of 102,155 shares worth more than $661,185.22. The most recent insider tranaction occured on April, 6th when CEO Richard Nolan Townsend sold 55,000 shares worth more than $312,950.00. Insiders at Lexeo Therapeutics own 5.3% of the company.
Learn More about insider trades at Lexeo Therapeutics. Information on this page was last updated on 4/6/2026.
